upgrad neutral lower pt
share fallen sinc sandoz launch gener formul unit
remodulin late march unit face acceler declin
top-lin ep dynam critic sell thesi howev
consensu estim alreadi impli eros revenu ep
challeng convict around downsid scenario
inde unit still like emerg stabil overal
top-lin non-gaap ep trough around option
ralinepag phase data could rejuven growth coupl nearli
cash point provid ballast valuat view
though case made around faster eros think roughli equal like
payor pressur and/or addit gener entrant fail materi upgrad
neutral sell
prescrib feedback limit payor pressur legal timelin
channel check kol suggest minim prescrib motiv switch start
patient gener remodulin payor pressur step ultim see
dynam larg depend upon addit gener entrant unclear us
addit gener entrant necessarili enter market sandoz
day exclus given on-going litig around subcutan segment
remodulin market inde recent disclos court timelin suggest
may get increment clariti front earli
overhaul model focus non-gaap estim notabl
lower remodulin estim per year reflect
gener pressur forecast sale
period establish non-gaap ep estim
respect vs con cash flow assumpt
tie sotp analysi lower sale estim new non-gaap oper
margin drive lower npv valuat price target
valuat upgrad neutral lower price
price target driven npv sum-of-the-part analysi
trade data key metric
compani account thomson reuter ub estim metric mark ub analyst adjust appli valuat base averag share price year base
share price may edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid
report singl factor make invest decis
ub research thesi map guid think report
 remodulin annual run-rat fall
possibl howev think challeng get confid remodulin meaning
under-perform consensu given uncertainti whether addit gener player
enter market litig sandoz complic decis inde
addit entrant materi unit like outperform estim
 unit lcm effort protect remodulin franchis long-term
potenti five main effort isr remun remopro bluetooth connect pump
trevyent isr remun pois nearest-term launch neither street
enamor effort howev kol feedback isr/remun posit
posit bias though doubt part narr evolv much
data weight backdrop street price
po expect share hold valu ascrib ralinepag
upgrad rate neutral sell share market price
risk gener remodulin unit top-lin ep profil see
balanc risk/reward downsid risk faster eros balanc upsid risk
addit gener entrant fail materi subcutan market remain inaccess and/or
unit multipl treprostinil life-cycl manag lcm effort protect remodulin revenu
stream backdrop see less clear cut neg setup share
close watch remodulin print monitor extent thesi play
channel check kol pulmonologist around motiv driver switch review court
document surround united-sandoz litig analysi consensu estim
revers engin model consensu estim suggest y/i eros
remodulin franchis price stock
upsid downsid
upsid downsid
upsid downsid
compani descript unit therapeut biotechnolog compani focus develop commerci novel
treatment address unmet medic need patient chronic
monitor thesi here well track
septemb end sandoz
 clariti sandoz litig
isr uptak clinic site
pend immin fda clearanc
devic unit intend launch isr
site plan expand site
see isr key piec unit remodulin
defens strategi kol feedback isr use
posit anticip
remodulin consensu estim current
impli declin q/q dont think
remodulin sale come meaning
estim driven physician resist switch
stabl pah patient brand remodulin payor
decis yet come on-line
close watch whether addit entrant enter
market immedi upon end
exclus whether compani take wait-
and-se approach given on-going litig
remodulin sale continu expect
similar dynam expect sale
least line current consensu estim
note phase dinutuximab program
current outsid street model expect
ahead dataset low compel orr
rate even os data would potenti
impact share
legal rule preliminari injunct
decis could provid impetu open
gener access subcutan segment turn
could shift payor attitud impact rate
remodulin eros
figur npv analysi chang valuat figur except per share figur
number share
model faster eros lower product margin
increment faster eros lower product margin
lower share base competit pah dynam lower product margin
model po slight tweak overal pah market model
figur total commerci pah valuat figur expect per share figur
pv cf
 remodulin annual run-rat fall
potenti howev think downsid street consensu unlik
given tepid prescrib interest gener treprostinil thu far greater payor
pressur like conting upon addit entrant uncertainti around
time entrant given question around access
subcutan segment agre
challeng face unit treprostinil busi struggl see unit
under-perform consensu remodulin estim think
would need materi warrant sell rate
discuss kol indic minim interest gener treprostinil bar
increas payor pressur review key sandoz vs unit smith file
indic us small probabl subcutan market open
gener
consensu remodulin forecast impli
brief overview remodulin setup gener pressur
septemb unit settl litig sandoz permit sandoz
enter market gener version remodulin treprostinil june
late march sandoz final launch version treprostinil give
day exclus ahead gener arriv sandoz unsurprisingli
put focu project eros remodulin current
consensu forecast estim ww sale y/i
sizeabl step-down con
figur remodulin expect erod
figur continu fall
view risk balanc given limit downsid estim
share held well latter half share price
fallen sinc sandoz launch sinc gener becam real
way think continu downsid share hing materi
eros remodulin sale beyond consensu estim outlin
howev base convers prescrib see minim motiv
switch proactiv moment bar greater payor pressur end
think pressur result follow addit entrant could
see decis push given on-going litig around gener
entrant access smith medic subcutan devic
kol feedback minim interest adopt gener treprostinil
interview pulmonologist gaug interest initi shift
prescrib behavior sandoz avail market overal
low interest adopt gener treprostinil moment particularli
patient stabl therapi kol note concern switch patient cite
potenti challeng titrat would justifi
potenti cost save though greater willing adopt gener
new start clinician still cite familiar comfort brand
kol feedback wait greater payor pressur shift behavior one
caveat discuss clinician spoke uniformli note
would shift gener payor forc impli payor
pressur yet materi think increas payor pressur like
depend upon greater price differenti vs brand remodulin turn like
requir addit entrant drive price lower see modest impact
remodulin sale ahead expir sandoz exclus
legal case unlik resolv shortli launch gener
treprostinil sandoz file lawsuit unit smith medic
unlaw impend competit subcutan segment work
smith medic cartridg subcutan deliveri import
right think sandoz access subcutan segment
drive total remodulin volum schedul case
recent disclos suggest hear preliminari injunct
occur late octob earliest base anticip investor
get clariti front earli
defens respons complaint motion dismiss due
complet wit deposit preliminari injunct proceed
figur schedul sandoz vs unit smith medic case
septemb complet expert deposit
hear date preliminari injunct
remodulin forecast base entranc gener updat
remodulin forecast lower forecast
rais assign share gener beyond
modestli consensu
given
assumpt modestli street given less
posit view remodulin lcm effort unit estim detail
figur
switch non-gaap estim addit switch non-gaap
estim sourc consensu non-gaap number improv
number volatil larg unhelp model base
busi given compani account stock-bas compens
impact ralinepag acquisit estim detail
figur figur
also detail non- reconcili figur well
crosswalk chang prior new estim
figur note chang appear larg due ralinepag acquisit
exclud model due uncertainti unit
go handl account
remodulin franchis beyond aforement remodulin chang
also modestli lower orenitram estim figur modifi
tyvaso estim figur remain meaning street
orenitram due competit tyvaso due
anticip continu sticki market lack gener penetr
cog decreas non-gaap cog
chang driven run-rat emerg
prior estim high given payment lilli decreas
adcirca eros acceler
 decreas non-gaap
saw moder spend believ requir spend
ralinepag clinic develop paid wind-down
clinic trial end late freedom-ev etc
sg decreas non-gaap sg
think justifi moder sg spend
rel expect expens manag given eros
remodulin
oper margin despit decreas oper expens
outlin lower remodulin sale forecast drive meaning lower
oper margin forecast margin decreas low
rang expect remain ralinepag launch
compani abl get leverag around product launch lower estim
remodulin tyvaso lower margin product drive
npv analysi group
figur chang remodulin franchis forecast
figur chang orenitram franchis forecast
figur chang tyvaso franchis forecast
chang prior model
pv cf
number share dilut
figur chang model non-gaap estim
figur gaap non-gaap reconcili
figur except ep fiscal year
sale market
interest incom expens
sale intang asset
number share basic
number share dilut
figur chang gaap estim
upsid downsid
upsid downsid
upsid downsid
upsid upsid scenario unit therapeut assum
gradual eros remodulin specif minim eros drive
higher ep scenario also model modest eros
tyvaso increment higher ralinepag estim
base base case model eros remodulin sale
rel sale eros tyvaso period
also model probabl success ralinepag
downsid downsid scenario assum rapid greater
remodulin sale declin well tyvaso
scenario also lower ralinepag po
unit therapeut biotechnolog compani focus
develop commerci novel treatment
address unmet medic need patient chronic
hypertens remodulin tyvaso orenitram adcirca
compani also market unituxin treatment high-
risk neuroblastoma found martin rothblatt
compani headquart silver spring md
expect biotech stock outperform broader
market basi attract growth rel
 within biotech long-term revenu
earn growth outlook key determin biotech
cycl organ pipelin develop strateg
acquisit pair financi metric sharehold
friendli program buy-back dividend etc like
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
valuat base npv sum-of-the-part analysi
downsid risk neutral thesi includ payor pressur switch
gener remodulin result greater expect eros
remodulin gener year greater competit across pah ralinepag
setback delay upsid risk neutral thesi includ better
anticip uptak remosynch implant pump system protect
remodulin franchis unexpect key clinic develop provid
